Bourgeon Capital Management’s Fate Therapeutics FATE Stock Holding History

Bourgeon Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-175	Closed	-$655	–	193
2023 Q4	$655	Hold	175	–	–	﹤0.01%	349
2023 Q3	$371	Hold	175	–	–	﹤0.01%	351
2023 Q2	$833	Hold	175	–	–	﹤0.01%	308
2023 Q1	$998	Hold	175	–	–	﹤0.01%	290
2022 Q4	$1.77K	Hold	175	–	–	﹤0.01%	312
2022 Q3	$4K	Hold	175	–	–	﹤0.01%	273
2022 Q2	$4K	Hold	175	–	–	﹤0.01%	259
2022 Q1	$7K	Hold	175	–	–	﹤0.01%	241
2021 Q4	$10K	Hold	175	–	–	﹤0.01%	217
2021 Q3	$10K	Hold	175	–	–	﹤0.01%	229
2021 Q2	$15K	Hold	175	–	–	﹤0.01%	213
2021 Q1	$14K	Hold	175	–	–	﹤0.01%	215
2020 Q4	$16K	Hold	175	–	–	﹤0.01%	197
2020 Q3	$7K	Hold	175	–	–	﹤0.01%	227
2020 Q2	$6K	Hold	175	–	–	﹤0.01%	211
2020 Q1	$4K	Hold	175	–	–	﹤0.01%	223
2019 Q4	$3K	Sell	175 -825	-83%	-$13.1K	﹤0.01%	217
2019 Q3	$16K	Buy	+1,000	New	+$19.2K	0.01%	160
2014 Q3	–	Sell	-15,384	Closed	-$97K	–	106
2014 Q2	$97K	Buy	+15,384	New	+$108K	0.05%	113

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bourgeon Capital Management's FATE Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 175 shares — an estimated $655 sold.

Bourgeon Capital Management first reported a position in FATE in Q2 2014 and held it in 19 quarters. The position peaked at $97K in Q2 2014. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

Bourgeon Capital Management reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 175 Fate Therapeutics shares in Q1 2024, an estimated $655.
Bourgeon Capital Management first reported a position in Fate Therapeutics in Q2 2014 and held it in 19 quarters.
Bourgeon Capital Management's Fate Therapeutics position peaked at $97K in Q2 2014.
167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.